[用于治疗肌肉骨骼感染的噬菌体-临床应用概述,未决问题和法律框架]。

IF 0.5
Markus Rupp, Tristan Ferry, Mohammadali Khan Mirzaei, Volker Alt, Li Deng, Nike Walter
{"title":"[用于治疗肌肉骨骼感染的噬菌体-临床应用概述,未决问题和法律框架]。","authors":"Markus Rupp, Tristan Ferry, Mohammadali Khan Mirzaei, Volker Alt, Li Deng, Nike Walter","doi":"10.1007/s00132-025-04690-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bacteriophages, or simply phages, are viruses that specifically infect and lyse bacteria. As antibiotic resistance becomes a growing global concern, phage therapy is gaining renewed attention as a targeted and effective treatment option. In orthopedics and trauma surgery-disciplines characterized by high rates of chronic and implant-associated infections-phages offer promising new therapeutic avenues, particularly in cases involving multidrug-resistant pathogens or when conventional surgery is limited.</p><p><strong>Current developments: </strong>Originally developed in the early 20th century, phage therapy lost prominence with the rise of antibiotics. Today, case studies and emerging clinical protocols-especially in the context of periprosthetic joint infections-demonstrate the potential of personalized phage cocktails and advanced delivery systems, such as hydrogels or intra-articular injections. Their specificity enables bacterial eradication while sparing the host microbiome.</p><p><strong>Regulatory situation: </strong>However, the regulatory landscape in the European Union poses significant challenges. Phages are classified as biological medicinal products, requiring comprehensive preclinical and clinical evaluation. While magistral production and compassionate use permit individual applications, broad clinical integration demands standardized protocols, accessible phage libraries, and robust quality control. Furthermore, safety concerns, including immunogenicity and systemic distribution, must be addressed through structured research.</p><p><strong>Conclusion: </strong>To fully realize the potential of phage therapy in orthopaedic infection management, interdisciplinary collaboration, targeted funding, and clinical trials are essential. Responsible implementation within expert centers can ensure efficacy and safety, paving the way for a controlled and evidence-based adoption of phages as a complementary strategy alongside traditional surgical and antibiotic treatments.</p>","PeriodicalId":74375,"journal":{"name":"Orthopadie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Bacteriophages for the treatment of musculoskeletal infections-An overview of clinical use, open questions, and legal framework].\",\"authors\":\"Markus Rupp, Tristan Ferry, Mohammadali Khan Mirzaei, Volker Alt, Li Deng, Nike Walter\",\"doi\":\"10.1007/s00132-025-04690-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Bacteriophages, or simply phages, are viruses that specifically infect and lyse bacteria. As antibiotic resistance becomes a growing global concern, phage therapy is gaining renewed attention as a targeted and effective treatment option. In orthopedics and trauma surgery-disciplines characterized by high rates of chronic and implant-associated infections-phages offer promising new therapeutic avenues, particularly in cases involving multidrug-resistant pathogens or when conventional surgery is limited.</p><p><strong>Current developments: </strong>Originally developed in the early 20th century, phage therapy lost prominence with the rise of antibiotics. Today, case studies and emerging clinical protocols-especially in the context of periprosthetic joint infections-demonstrate the potential of personalized phage cocktails and advanced delivery systems, such as hydrogels or intra-articular injections. Their specificity enables bacterial eradication while sparing the host microbiome.</p><p><strong>Regulatory situation: </strong>However, the regulatory landscape in the European Union poses significant challenges. Phages are classified as biological medicinal products, requiring comprehensive preclinical and clinical evaluation. While magistral production and compassionate use permit individual applications, broad clinical integration demands standardized protocols, accessible phage libraries, and robust quality control. Furthermore, safety concerns, including immunogenicity and systemic distribution, must be addressed through structured research.</p><p><strong>Conclusion: </strong>To fully realize the potential of phage therapy in orthopaedic infection management, interdisciplinary collaboration, targeted funding, and clinical trials are essential. Responsible implementation within expert centers can ensure efficacy and safety, paving the way for a controlled and evidence-based adoption of phages as a complementary strategy alongside traditional surgical and antibiotic treatments.</p>\",\"PeriodicalId\":74375,\"journal\":{\"name\":\"Orthopadie (Heidelberg, Germany)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orthopadie (Heidelberg, Germany)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00132-025-04690-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopadie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00132-025-04690-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:噬菌体,或简称噬菌体,是特异性感染和溶解细菌的病毒。随着抗生素耐药性日益成为全球关注的问题,噬菌体治疗作为一种有针对性和有效的治疗选择正在重新受到关注。在骨科和创伤外科这些以慢性感染和植入物相关感染高发为特征的学科中,噬菌体提供了有希望的新治疗途径,特别是在涉及多药耐药病原体或传统手术受限的情况下。当前发展:噬菌体疗法最初是在20世纪初发展起来的,随着抗生素的兴起而失去了地位。今天,案例研究和新出现的临床方案——特别是在假体周围关节感染的背景下——证明了个性化噬菌体鸡尾酒和先进的给药系统(如水凝胶或关节内注射)的潜力。它们的特异性使细菌根除,同时保留宿主微生物组。监管形势:然而,欧盟的监管形势带来了重大挑战。噬菌体属于生物医药产品,需要进行临床前和临床综合评价。虽然地方生产和医疗使用允许个人应用,但广泛的临床整合需要标准化的协议、可访问的噬菌体库和强有力的质量控制。此外,安全性问题,包括免疫原性和全身分布,必须通过结构化的研究来解决。结论:要充分发挥噬菌体治疗在骨科感染管理中的潜力,需要跨学科合作、有针对性的资助和临床试验。专家中心内负责任的实施可确保疗效和安全性,为有控制地、以证据为基础采用噬菌体作为传统手术和抗生素治疗的补充策略铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Bacteriophages for the treatment of musculoskeletal infections-An overview of clinical use, open questions, and legal framework].

Background: Bacteriophages, or simply phages, are viruses that specifically infect and lyse bacteria. As antibiotic resistance becomes a growing global concern, phage therapy is gaining renewed attention as a targeted and effective treatment option. In orthopedics and trauma surgery-disciplines characterized by high rates of chronic and implant-associated infections-phages offer promising new therapeutic avenues, particularly in cases involving multidrug-resistant pathogens or when conventional surgery is limited.

Current developments: Originally developed in the early 20th century, phage therapy lost prominence with the rise of antibiotics. Today, case studies and emerging clinical protocols-especially in the context of periprosthetic joint infections-demonstrate the potential of personalized phage cocktails and advanced delivery systems, such as hydrogels or intra-articular injections. Their specificity enables bacterial eradication while sparing the host microbiome.

Regulatory situation: However, the regulatory landscape in the European Union poses significant challenges. Phages are classified as biological medicinal products, requiring comprehensive preclinical and clinical evaluation. While magistral production and compassionate use permit individual applications, broad clinical integration demands standardized protocols, accessible phage libraries, and robust quality control. Furthermore, safety concerns, including immunogenicity and systemic distribution, must be addressed through structured research.

Conclusion: To fully realize the potential of phage therapy in orthopaedic infection management, interdisciplinary collaboration, targeted funding, and clinical trials are essential. Responsible implementation within expert centers can ensure efficacy and safety, paving the way for a controlled and evidence-based adoption of phages as a complementary strategy alongside traditional surgical and antibiotic treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信